FDA released the original post marketing requirement (PMR) for some abuse-deterrent (AD) opioids to show that the properties intended to deter misuse and abuse of the product actually result in a meaningful decrease in misuse and abuse, and their related clinical outcomes of addiction, overdose, and death, in post-approval settings. It will be replaced with a two-phased study approach in order to obtain the data needed to fulfill the PMR because the agency has determined that a sequential approach will be more responsive to the uncertainties inherent to this situation – namely, a study that is dependent on adequate uptake of the product in the market.